The federal government and Emergent BioSolutions Inc. terminated a pandemic-preparedness contract after the contract drug manufacturer experienced problems manufacturing Covid-19 vaccines.
Emergent, based in Gaithersburg, Md., said Thursday the termination reduced the total value of its contract to $470.9 million from $650.8 million.
